drugset / Trial / NCT02919059

Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

NCT02919059

Phase 4 Unknown 159 enrolled IInstituto Gallego de Medicina Vascular
RandomizedParallel-groupDouble-blindTreatment

Summary

This superiority of central pressure versus peripheral measures to predict cardiovascular events has also been reported in general population or in elder people

Timeline

Start
2016-12-13
Primary completion
2018-12
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg
Comparator Glimepiride Small molecule 4 mg